Aryl substituted bicycle heteroaryl compounds
AssigneeBristol-Myers Squibb Company
InventorsXiaojun Zhang, Xiaofan Zheng, Louis S. Chupak
Life of this patent
Estimating the term…
Abstract
Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one R3 is H and the other R3 is an aryl group substituted with zero to 3 R3a; and R1, R2, and R3a are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors for the inhibition or prevention of platelet aggregation, and the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. Also disclosed are methods of using such compounds for the treatment of human papillomavirus. Additionally, pharmaceutical compositions comprising at least one compound of Formula (I) are disclosed.
Claims4
A method for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder, comprising the steps of administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (II), (III), or (IV):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is —OCH3, —OCHF2, or —CH2OCH3;
- R2 is H, F, Cl, Br, —OH, —CN, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C2-4 alkenyl, C2-4 alkenyl, or —C(O)O(C1-6 alkyl);
- R3 is phenyl or naphthalenyl substituted with zero to 2 R3a;
- and
- R3a, at each occurrence, is independently F, Cl, Br, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 alkoxy, or C1-3 fluoroalkoxy;
- wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart or in the peripheral circulation.
A method of inhibiting or preventing platelet aggregation, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (II), (III), or (IV):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is —OCH, —OCHF, or —CH2OCH3;
- R2 is H, F, Cl, Br, —OH, —CN, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C2-4 alkenyl, C2-4 alkynyl, or —C(O)O(C1-6 alkyl);
- R3 is phenyl or naphthalenyl substituted with zero to 2 R3a;
- and
- R3a, at each occurrence, is independently F, Cl, Br, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 alkoxy, or C1-3 fluoroalkoxy.
A method for the treatment of human papillomavirus, comprising the steps of administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (II), (III), or (IV):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is —OCH, —OCHF, or —CH2OCH3;
- R2 is H, F, Cl, Br, —OH, —CN, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 hydroxyalkyl, C2-4 alkenyl, C2-4 alkynyl, or —C(O)O(C1-6 alkyl);
- R3 is phenyl or naphthalenyl substituted with zero to 2 R3a;
- and
- R3a, at each occurrence, is independently F, Cl, Br, C1-3 alkyl, C1-3 fluoroalkyl, C1-3 alkoxy, or C1-3 fluoroalkoxy.
Dependencies are inferred from the claim text.